Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 6, 1999, Pages 699-704

  Wolf, Hermann K ^a   Andreou, Pantelis ^b   Bata, Iqbal R ^a   Comeau, Donna G ^b   Gregor, Ronald D ^a   Kephart, George ^b   MacLean, David R ^b   Sketris, Ingrid ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANADA; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG USE; FEMALE; HEALTH CARE AVAILABILITY; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; QUESTIONNAIRE; REGRESSION ANALYSIS; SELF REPORT; SEX RATIO; SYSTOLIC BLOOD PRESSURE;

EID: 0033592333     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Guidelines Subcommittee. 1999 World Health Organization - International-Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999;11:905-16.
2. Jackson R, Yee RL, Priest P, Shaw L, Beaglehole R. Trends in coronary heart disease risk factors in Auckland 1982-94. N Z Med J 1995;108(1011):451-4.
3. Bennett S. Cardiovascular risk factors in Australia: trends in socioeconomic inequalities. J Epidemiol Community Health 1995;49(4):363-72.
4. Sakata K, Labarthe DR. Changes in cardiovascular disease risk factors in three Japanese national surveys 1971-1990. J Epidemiol 1996;6(2):93-107.
5. Burt VL, Culter JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26(1):60-9.
6. Luepker RV, Rosamond WD, Murphy R, Sprafka JM, Folsom AR, McGovern PG, et al. Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart Survey. Circulation 1993;88(5 pt 1):2172-9.
7. Kastarinen MJ, Salomaa VV, Vartiainen FA, Jousilahti PJ, Tuomilehto JO, Puska PM, et al. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998;16(9):1379-87.
8. Hoffineister H, Mensink GB, Stolzenberg H. National trends in risk factors for cardiovascular disease in Germany. Prev Med 1994;23(2);197-205.
9. Gregor R, Bata I, Eastwood B, Wolf H. Ten-year trends of heart disease risk factors in the Halifax County MONICA population. Can J Cardiol 1998;14(8):1017-24.
10. Gross TP, Wise RP, Knapp DE. Antihypertensive drug use. Trends in the United States from 1973 to 1985. Hypertension 1989;13(5 Suppl):1113-8.
11. Hume AL, Barbour ALM, Willey CJ, Assaf AR, Lapane KL, Carleton RA. Changing trends in antihypertensive therapy in two New England communities during the 1980s. Pharmacotherapy 1993;13(3):244-51.
12. Glynn RJ, Brock DB, Harris T, Havlik RJ, Chrischilles FA, Ostfeld AM, et al. Use of antihypertensive drugs and trends in blood pressure in the elderly. Arch Intern Med 1995;155(17):1855-60.
13. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155(8):829-37.
14. Schueler K. Cost-effectiveness issues in hypertension control. Can J Public Health 1994;85(2 Suppl):554-6.
15. Eastwood BJ, Gregor RD, MacLean DR, Wolf HK. Effects of recruitment-strategy on response rates and risk factor profile in two cardiovascular surveys. Int J Epidemiol 1996;25(4):763-9.
16. Nova Scotia Department of Health, Heart Health Nova Scotia. The Nova Scotia Health Survey, 1995. Halifax: The Department; 1996.
17. World Health Organization. Anatomical therapeutic chemical (ATC) classification index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 1993.
18. World Health Organization. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 1996.
19. Gillis M, editor. Compendium of pharmaceuticals and specialties. 32nd ed. Ottawa: Canadian Pharmaceutical Association; 1997.
20. Atlantic Pharmaceutical Services. Atlantic pharmaceutical services incorporated pricing guide. Halifax: Atlantic Pharmaceutical Services; 1995.
21. Wheeler-Usher D, Hatcher C, Dawn F, editors. Nova Scotia formulary, appendix VIII APSI price guide. Halifax: Nova Scotia Department of Health; 1996.
22. Hense HW, Koivisto AM, Kuulasmaa K, Zaborskis A, Kupsc W, Tuomilehto J, et al. Assessment of the blood pressure measurement quality in the baseline surveys of the WHO MONICA Project. J Hum Hypertens 1995;9:935-46.
23. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10(10 pt 1):1097-102.
24. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25(3):305-13.
25. Haynes R. The determinants of compliance: the disease and the mechanism of treatment. In: Haynes R, Taylor D, Sackett D, editors. Compliance in healthcare. Baltimore: John Hopkins University Press; 1979. p. 49-62.
26. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991;121(2 pt 2):664-9.
27. Hosie J, Wiklund I. Managing hypertension in general practice: Can we do better? J Hum Hypertens 1995;9(2 Suppl) 515-8.
28. Yasin S. Detecting and improving compliance. Is concordance the solution? Aust Fam Physician 1998;27(4):255-60.
29. Logan AG. Report of the Canadian Hypertension Society's Consensus Conference on the management of mild hypertension. CMAJ 1984;131(9):1053-7.
30. Myers MG, Carruthers SG, Leenen FHH, Haynes RB. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. CMAJ 1989;140(10):1141-6.
31. Penrose A, Dovey S, Tilyard M. Trends in antihypertensive prescribing. N Z Med J 1996;109(1014):4-7.
32. McAlister FA, Teo KK, Lewanczuk RZ, Wells G, Montague TJ. Contemporary practice patterns in the management of newly diagnosed hypertension. CMAJ 1997;157(1):23-30.
33. Laplante P, Niyonsenga T, Delisle K, Vonasse N, Vanasse A, Grant AM, et al. Habitudes de traitment de l'hypertension en 1996. Can Fam Physician 1998;44:306-12.
34. Birkett NJ. The effect of alternative criteria for hypertension on estimates of prevalence and control. J Hypertens 1997;15(3):237-44.
35. McAlister F, Moerman S, Lewanczuk R. Cost of antihypertensive medications in Alberta. Can J Clin Pharmacol 1995;2(4):180-4.